Core Viewpoint - Veracyte (VCYT) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance and Outlook - The upgrade indicates an improvement in Veracyte's underlying business, which is expected to positively influence its stock price [5]. - Veracyte is projected to earn $1.20 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 0.8% [8]. Analyst Sentiment and Consensus - Over the past three months, the Zacks Consensus Estimate for Veracyte has increased by 10.6%, indicating a positive trend in analyst sentiment [8]. - The Zacks rating system maintains a balanced approach, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, highlighting Veracyte's strong position in earnings estimate revisions [9][10].

PART I. — FINANCIAL INFORMATION [Condensed Consolidated Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for the quarter ended March 31, 2025, show a significant turnaround, with the company reporting a net income of $7.0 million compared to a net loss of $1.9 million in the prior-year period, driven by an 18% increase in total revenue, primarily from testing services, while total assets increased slightly to $1.315 billion and total liabilities decreased, strengthening the company's balance sheet [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets were $1.315 billion, a slight increase from $1.300 billion at year-end 2024, driven by an increase in short-term investments and goodwill, partially offset by a decrease in cash and cash equivalents, while total liabilities decreased to $120.5 million from $124.1 million, and stockholders' equity grew to $1.195 billion Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $186,120 | $239,087 | | Short-term investments | $101,235 | $50,354 | | Total current assets | $383,152 | $372,267 | | Goodwill | $754,272 | $745,800 | | Total assets | $1,315,411 | $1,300,035 | | **Liabilities & Equity** | | | | Total current liabilities | $75,125 | $78,633 | | Total liabilities | $120,475 | $124,069 | | Total stockholders' equity | $1,194,936 | $1,175,966 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, Veracyte reported total revenue of $114.5 million, an 18% increase year-over-year, achieving income from operations of $2.9 million, a significant improvement from a loss of $4.7 million in Q1 2024, resulting in net income of $7.0 million, or $0.09 per diluted share, compared to a net loss of $1.9 million, or ($0.02) per share, in the prior-year period Q1 2025 vs. Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Testing revenue | $107,309 | $90,303 | | Total revenue | $114,473 | $96,844 | | Gross profit | $79,508 | $62,468 | | Income (loss) from operations | $2,904 | $(4,656) | | Net income (loss) | $7,047 | $(1,864) | | Diluted EPS | $0.09 | $(0.02) | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the first three months of 2025, net cash provided by operating activities was $5.4 million, a reversal from the $9.0 million used in the same period of 2024, while net cash used in investing activities was $51.8 million, primarily for the purchase of short-term investments, and net cash used in financing activities was $6.5 million, mainly for tax payments on vested restricted stock units Cash Flow Summary for Three Months Ended March 31 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $5,362 | $(8,966) | | Net cash (used in) provided by investing activities | $(51,818) | $2,878 | | Net cash used in financing activities | $(6,484) | $(864) | | Net decrease in cash, cash equivalents and restricted cash | $(52,866) | $(7,060) | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the 18% year-over-year revenue growth to a 23% increase in diagnostic test volume, particularly for Decipher Prostate and Afirma tests, with gross profit improving by 27% to $79.5 million, leading to profitability with a net income of $7.0 million, while key strategic focuses include expanding the minimal residual disease (MRD) portfolio and transitioning more tests to IVD formats for global markets, maintaining a strong liquidity position with $287.4 million in cash, cash equivalents, and short-term investments [Overview](index=25&type=section&id=Overview) Veracyte is a global diagnostics company focused on providing tests for cancer diagnosis, prognosis, and treatment decisions, operating with a dual model of laboratory developed tests (LDTs) in the U.S. and in vitro diagnostics (IVDs) internationally, with a key strategic initiative being the expansion into minimal residual disease (MRD) testing to monitor post-treatment cancer recurrence - The company's current U.S. offerings include tests for prostate (Decipher Prostate), thyroid (Afirma), breast (Prosigna), and bladder (Decipher Bladder) cancer[103](index=103&type=chunk) - Veracyte serves global markets through two models: centralized CLIA labs in the U.S. and IVD test distribution primarily outside the U.S.[104](index=104&type=chunk) - The company is expanding its portfolio to include minimal residual disease (MRD) assays to monitor therapeutic success and patient outcomes[105](index=105&type=chunk) [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Total revenue for Q1 2025 increased by 18% to $114.5 million, driven by a 19% rise in testing revenue from higher volumes, with gross profit growing 27% to $79.5 million, while operating expenses increased 14% to $76.6 million, largely due to higher general and administrative costs, including one-time expenses related to a subsidiary's bankruptcy proceeding and an acquisition, despite which the company shifted from an operating loss of $4.7 million in Q1 2024 to an operating income of $2.9 million in Q1 2025 Q1 2025 vs. Q1 2024 Results of Operations (in thousands) | Line Item | Q1 2025 | Q1 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $114,473 | $96,844 | $17,629 | 18% | | Gross profit | $79,508 | $62,468 | $17,040 | 27% | | Total operating expenses | $76,604 | $67,124 | $9,480 | 14% | | Income (loss) from operations | $2,904 | $(4,656) | $7,560 | (162)% | | Net income (loss) | $7,047 | $(1,864) | $8,911 | (478)% | - Testing revenue increased by **$17.0 million (19%)** due to a **23% increase in test volume**, primarily from Decipher Prostate and Afirma tests[138](index=138&type=chunk) - General and administrative expenses rose by **$7.6 million (29%)**, driven by a **$7.3 million increase in professional fees**, which included **$3.8 million** for a subsidiary's bankruptcy proceeding and a **$3.3 million** payment for the C2i Acquisition[146](index=146&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, Veracyte had a strong liquidity position with $287.4 million in cash, cash equivalents, and short-term investments, having generated $5.4 million in cash from operations in Q1 2025, and management believes existing cash and future cash flows from revenue will be sufficient to meet anticipated requirements for at least the next 12 months, with material future cash requirements including operating lease payments totaling $93.2 million and potential acquisition-related contingent consideration payments up to $26.0 million - The company held **$287.4 million** in cash, cash equivalents, and short-term investments as of March 31, 2025[150](index=150&type=chunk) - Management believes current liquidity is sufficient for at least the next 12 months[152](index=152&type=chunk) - Material cash requirements include **$93.2 million** in future minimum lease payments and up to **$26.0 million** in contingent consideration for the C2i and nCounter acquisitions[153](index=153&type=chunk)[154](index=154&type=chunk)[155](index=155&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from interest rates, foreign currency fluctuations, and inflation, however, management does not believe these risks have had a material effect on the company's financial condition or operating results to date, and a hypothetical 10% change in interest rates or the U.S. dollar-to-Euro exchange rate would not have a material impact - Interest Rate Risk: Exposure exists through **$287.4 million** in cash and investments, but a hypothetical **10% change** in rates is not considered material[165](index=165&type=chunk) - Foreign Currency Risk: Exposure from **$3.4 million** in Euro-denominated deposits is not considered material[166](index=166&type=chunk) - Inflation Risk: The company is facing inflation headwinds in costs but does not believe it has had a material effect on results[167](index=167&type=chunk) [Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Based on an evaluation as of March 31, 2025, the company's Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were effective at a reasonable assurance level, and there were no material changes to the company's internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures were effective as of March 31, 2025[170](index=170&type=chunk) - No changes in internal control over financial reporting occurred in Q1 2025 that have materially affected, or are reasonably likely to materially affect, internal controls[171](index=171&type=chunk) PART II. — OTHER INFORMATION [Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) On May 1, 2025, Veracyte initiated legal action by filing a complaint in federal court against Sonic Healthcare USA, Inc., alleging infringement of three of Veracyte's patents concerning molecular testing of thyroid nodules and seeking damages and injunctive relief - On May 1, 2025, Veracyte filed a patent infringement complaint against Sonic Healthcare USA, Inc. related to thyroid nodule testing technology[90](index=90&type=chunk) - The company is seeking treble damages, attorneys' fees, costs, and an injunction against Sonic Healthcare[90](index=90&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) The company states that there have been no material changes to the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 - There have been no material changes in the company's risk factors from those described in the most recent Annual Report on Form 10-K[174](index=174&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the quarter - None[175](index=175&type=chunk) [Other Information](index=39&type=section&id=Item%205.%20Other%20Information) During the first quarter of 2025, director Robert Epstein adopted a new Rule 10b5-1 trading plan to sell an aggregate of 21,473 shares of common stock, with no other Section 16 officers adopting, modifying, or terminating such plans - Director Robert Epstein adopted a new Rule 10b5-1 trading plan on March 6, 2025, to sell **21,473 shares**, with the first trade scheduled for around June 5, 2025[178](index=178&type=chunk)

Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.29 per share when it actually produced earnings of $0.36, delivering a surprise of 24.14%. Over the last four quarters, th ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $114.5 million, representing an 18% year-over-year growth, driven by testing revenue growth of 19% year-over-year [6][28] - Adjusted EBITDA margin was 21.6%, significantly higher than expected, with a strong balance sheet of $287 million in cash and short-term investments [6][28] - Non-GAAP gross margin was 72%, up approximately 400 basis points year-over-year, while testing gross margin was 74%, up approximately 200 basis points [31] Business Line Data and Key Metrics Changes - Decipher saw a 37% year-over-year volume growth, resulting in approximately 22,600 tests and revenue growth of 33% [7][9] - Afirma experienced a 10% year-over-year volume growth, resulting in approximately 15,500 tests, but revenue growth was lower at 6% due to prior period collection benefits [12][66] - Product line revenue was $3.6 million, up 1% year-over-year, while biopharmaceutical and other revenue was also $3.6 million, up 19% year-over-year [30] Market Data and Key Metrics Changes - The company reported a record number of ordering providers for Decipher, up over 20% from the prior year, indicating strong market penetration [7][60] - The Decipher prostate metastatic test is expected to expand the population eligible for testing by an additional 30,000 patients annually [10] - The MRD platform is being developed for muscle invasive bladder cancer, with a commercial launch expected in the first half of 2026 [17] Company Strategy and Development Direction - The company is focused on expanding its existing tests, Decipher and Afirma, and launching new products like Prosigna in the U.S. breast cancer market [15][16] - Strategic initiatives include international expansion and addressing novel cancer challenges with innovative products [6][25] - The company aims to leverage its Veracyte Diagnostics platform to generate clinical evidence and support product adoption [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong growth despite a challenging macro environment, citing ongoing durability in core testing business [6][34] - The company reiterated its 2025 testing revenue guidance of $470 million to $480 million, raising adjusted EBITDA margin guidance to 22.5% [33][34] - Management highlighted the importance of evidence generation and reimbursement in ensuring successful product launches [49][90] Other Important Information - The company is undergoing a restructuring process in France, with its subsidiary Veracyte SAS filing for bankruptcy, which may impact product development timelines [21][22] - The launch of the Prosigna LDT is expected in mid-2026, targeting over 300,000 patients diagnosed with breast cancer annually in the U.S. [15][16] Q&A Session Summary Question: Thoughts on portfolio optimization and pipeline value of MRD and nasal swab - Management emphasized a focus on portfolio management and expanding indications, with confidence in the pipeline value of MRD and nasal swab initiatives [36][38][42] Question: Organizational readiness for upcoming product launches - Management discussed the importance of evidence generation and thoughtful launch plans, ensuring investments align with growth opportunities [48][49][53] Question: Clarification on guidance and Afirma growth rate - Management clarified that the guidance reflects testing revenue only, with expectations of high single-digit growth for Afirma [62][66] Question: Differentiation of Prosigna in a competitive market - Management highlighted the evidence-based differentiation of Prosigna and the strategy to gain market share similar to Decipher's success [72][75]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $114.5 million, representing an 18% year-over-year growth, driven by testing revenue growth of 19% year-over-year [5][28] - Adjusted EBITDA margin was 21.6%, significantly higher than expected, with a strong balance sheet of $287 million in cash and short-term investments [5][28] - Non-GAAP gross margin was 72%, up approximately 400 basis points year-over-year, while testing gross margin was 74%, up approximately 200 basis points [30][32] Business Line Data and Key Metrics Changes - Decipher testing revenue grew by 33% year-over-year, with volume growth of 37%, totaling approximately 22,600 tests [6][28] - Afirma testing volume increased by 10% year-over-year, resulting in approximately 15,500 tests, but revenue growth was lower due to prior period collection benefits [12][28] - Product line revenue was $3.6 million, up 1% year-over-year, while biopharmaceutical and other revenue was also $3.6 million, up 19% year-over-year [29] Market Data and Key Metrics Changes - The company reported a record number of ordering providers for Decipher, up over 20% from the prior year, indicating strong market penetration [6][28] - The Decipher prostate metastatic test is expected to launch broadly in June 2025, expanding the population eligible for testing [9][10] - The MRD platform is advancing with a focus on muscle invasive bladder cancer, with commercial launch expected in the first half of 2026 [18][19] Company Strategy and Development Direction - The company is focused on expanding its existing tests, Decipher and Afirma, and launching new products like Prosigna in the U.S. breast cancer market [16][17] - Strategic initiatives include international expansion and addressing novel cancer challenges with innovative products [6][25] - The company aims to leverage its Veracyte Diagnostics platform to generate clinical evidence and support product adoption [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong growth despite a challenging macro environment, citing positive trends in testing volume and provider engagement [5][6] - The company reiterated its 2025 testing revenue guidance of $470 million to $480 million, raising adjusted EBITDA margin guidance to 22.5% [33][34] - Management emphasized the importance of evidence generation and reimbursement for new product launches, ensuring organizational readiness for upcoming launches [48][52] Other Important Information - The company is undergoing a bankruptcy process for its French subsidiary, Veracyte SAS, which will not impact its overall strategy or revenue models for the next five years [21][24] - The launch of the Prosigna LDT is expected to begin in mid-2026, targeting a significant market of over 300,000 breast cancer patients annually in the U.S. [16][17] Q&A Session Summary Question: Thoughts on portfolio optimization and pipeline value of MRD and nasal swab - Management is focused on portfolio management, ensuring investments have appropriate evidence and reimbursement, and is excited about the broad pipeline of new products [37][40] - The MRD and nasal swab initiatives are seen as having significant market potential, with upcoming milestones expected to validate their value [42][43] Question: Organizational readiness for upcoming product launches - The company has a thoughtful launch plan in place, ensuring that investments are made in line with growth opportunities and that commercial activities are well-prepared [48][52] Question: Clarification on guidance and growth expectations for Afirma - Afirma is expected to see high single-digit revenue growth for the year, with volume growth driven by prior period collections and market dynamics [66][67] Question: Differentiation of Prosigna in a competitive market - Management believes Prosigna is differentiated based on evidence generation and a strong playbook similar to Decipher, aiming to gain market share in the U.S. [73][75]

Financial Performance - GAAP Gross Profit for the three months ended March 31, 2025 was $79508 thousand, resulting in a GAAP Gross Margin of 695%[42] - Non-GAAP Gross Profit for the three months ended March 31, 2025 was $82613 thousand, yielding a Non-GAAP Gross Margin of 722%[42] - Adjusted EBITDA for the three months ended March 31, 2025, reached $24715 thousand, representing 216% of revenue[47] - GAAP Net Income for the three months ended March 31, 2025, was $7047 thousand, or 62% of revenue[47] - Non-GAAP Net Income for the three months ended March 31, 2025, amounted to $24476 thousand[55] Strategic Initiatives and Product Development - Prosigna LDT is expected to be commercially available in mid-2026[19] - The company submitted a tech assessment to MolDx for MIBC in March 2025, with commercial launch and reimbursement expected in the first half of 2026[22] - NIGHTINGALE pivotal trial enrollment is approximately 95% complete, with completion expected in Q3[28] Operational Expenses - Non-GAAP research and development expenses for the three months ended March 31, 2025, were $15654 thousand[44] - Non-GAAP sales and marketing expenses for the three months ended March 31, 2025, totaled $22496 thousand[44] - Non-GAAP general and administrative expenses for the three months ended March 31, 2025, were $22348 thousand[44]

Exhibit 99.1 Veracyte Announces First Quarter 2025 Financial Results Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2025 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by stron ...

Core Insights - Veracyte (VCYT) is experiencing growth driven by its Afirma and Decipher tests, with expectations for continued expansion in the coming years [1][6] - The company has outperformed the industry and S&P 500, with a market capitalization of $2.48 billion and an earnings yield of 3.9% [2] - Despite strong performance, Veracyte faces challenges from declining biopharmaceutical revenues and macroeconomic factors [9][10] Afirma Test Performance - The Afirma solution has shown resilience, with over 16,300 tests delivered in Q4, an 8% year-over-year increase [3] - Revenue growth of 4% is attributed to deeper market penetration and new customer acquisitions [3] - A significant milestone was achieved with expanded Medicare reimbursement for Bethesda V thyroid nodules, leading to an 80% year-over-year revenue increase for these cases [4] Decipher Test Growth - The Decipher Prostate Cancer tests have seen substantial growth, with Q4 recording 22,400 tests, a 45% increase year-over-year [5] - The test is the only NCCN-recommended gene expression test for prostate cancer treatment decisions, enhancing its market position [5] - Recent approvals for metastatic assessment and New York State clearance are expected to further boost Decipher's growth [6] Long-Term Growth Strategies - Veracyte is focused on long-term growth through identifying medical needs, developing tests, and securing clinical evidence [7] - The NIGHTINGALE study for nasal swab diagnostics is progressing well, with over 85% of the target enrollment completed [7] - The company plans to launch its first MRD indication targeting muscle-invasive bladder cancer in the first half of 2026 [7] Financial Performance and Estimates - The Zacks Consensus Estimate for Veracyte's 2025 earnings per share has increased by 34.8% to $1.24, with revenues projected at $488.7 million, a 9.6% rise from the previous year [11]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score emphasizes a company's financial health and future growth potential [4] - Momentum Score focuses on stocks with upward or downward price trends [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [9] Stock Recommendation: Veracyte (VCYT) - Veracyte is a diagnostics company specializing in cancer detection and treatment, with a diverse portfolio of genomic tests [12] - VCYT holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of B, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 4.2% for the current fiscal year, with upward revisions in earnings estimates [13] - VCYT's average earnings surprise stands at 515.9%, making it a compelling option for growth investors [13][14]

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term moving ...